Most people with H. pylori don’t have any symptoms.

When the infection leads to an ulcer, symptoms may include abdominal (stomach) pain, especially when your stomach is empty at night or a few hours after meals. The pain is described as a gnawing pain, and it may come and go.

Symptoms which may be associated with H. pylori infection can include:

1. excessive burping
2. feeling bloated
3. nausea
4. heartburn
5. fever
6. lack of appetite, or anorexia
7. unexplained weight loss

H. pylori survives the acidic conditions of the stomach by making an enzyme called urease, which breaks down urea into carbon dioxide and ammonia, thereby neutralising the stomach acid. The less acidic gastric environment means that pathogens are not killed off as effectively and this can lead to further issues in the stomach, intestines and therefore other parts of the body.

H. pylori also stimulates histamine producing cells and increases the relevant enzyme, thereby increasing histamine production. This increases inflammation, primarily in the stomach and gut lining and can cause a wide range of symptoms around the body, such as those related to histamine intolerance.

H. pylori uses the ammonium (ammonia is converted to ammonium) to survive the gastric acid and thrive in the stomach.

Toxaprevent Medi Plus Sachets contain MANC® particles which binds directly to histamine and ammonium in the stomach.

MANC® is a clean and safe form of clinoptilolite zeolite that absorbs and eliminates ammonium from the stomach and intestines. MANC® also binds and eliminates histamine produced by H. pylori, thereby alleviating the associated digestive problems. This also stops histamine being absorbed by the body, where it would otherwise be free to circulate and cause histamine modulated symptoms in areas where histamine receptors are present e.g. lungs, heart, brain, skin.

MANC® also binds and eliminates the protective shield of ammonium which allows H. pylori to survive in the stomach. Over 5 days, the ammonium shield can be slowly broken down, leaving the bacteria exposed to the acidic stomach conditions. Gastric acid is then able to kill off the infestation and eliminate H. pylori, stopping further production of ammonium and reducing the burden on the liver created from H. pylori. This also optimises the level of acid in the stomach, ensuring that there isn’t too much acid, nor too little acid. Once the MANC® has bound to toxins such as ammonium, it travels through the digestive tract where it is passed out with the body’s natural bowel movements.

• MANC® particles are the cleanest form of zeolite, meaning it will not poison your body with anything it has already absorbed. MANC® particles are deeply cleansed of any toxins they may have absorbed before being mined from the ground.
• MANC® particles are derived from clinoptilolite zeolite, the most effective form of zeolite for its ability to strongly bind with various toxic substances
• MANC® particles stay in the gut and are not absorbed through the intestinal barrier into the body, meaning the body doesn’t have to metabolise MANC® particles through the liver and kidneys. Instead, MANC® particles are flushed from the body via natural bowel movements, taking the toxic substances they have bound to along with them
• MANC® particles are vacuum sealed in their packaging so they don’t absorb any toxins in the air before you consume them
• MANC® particles are classified as medical devices, meaning they don’t interfere with the body’s processes and the scientific evidence that supports its use has been evaluated by an independent body (TUV Rheinland)
• MANC® particles have been thoroughly tested and come in preparations which ensure they aren’t broken down in stomach acid and can’t release aluminium into the body, unlike other zeolite product (see It is known that clinoptilolite zeolite breaks down in acid and releases aluminium. Does this mean MANC® particles could poison me with aluminium?)
• MANC® particles only take out toxic substances and leave essential minerals and micronutrients untouched in the body
• Froximun AG, the manufacturers of MANC® particles, are obliged to have a dedicated responsible person as part of their quality control system who, in the unlikely case that someone has an adverse reaction to MANC® particles, can be contacted to record the adverse event and seek further advice from their expert medical service.

The surface structures on L. reuteri DSM17648 contains adhesion molecules that recognise and adhere to the surface structures of H.pylori in the gastric mucosa. Once bound, the H. pylori will be flushed from the stomach alongside the L. reuteri by natural bowel movement.

Interestingly, the aggregation activity was preserved when the cells were spray dried. It can therefore be show that the binding is due to specific surface molecules of the L. reuteri DSM17648 cells which are strain specific and are resistant to such process steps.⁶

These results have again been repeated in a small in vivo study of 22 people which showed a significant decrease of H. pylori stomach colonisation after lactobacillus reuteri DSM17648 supplementation in asymptomatic subjects with detectable H. pylori infection.⁷

A further study combined L. reuteri DSM17648 in association with extract of deglycyrrhizinated liquorice and calcium carbonate vs triple therapy. The study found that this combination was successful in eradicating H. pylori in over 50% of patients and had good tolerability and compliance.⁸

Alternatively, using the L. reuteri DSM17648 on its own has shown beneficial results even with young children.¹⁰

References
1. https://www.ncbi.nlm.nih.gov/pubmed/28456631
2. Blaser, M.J. Helicobacters are indigenous to the human stomach: Duodenal ulceration is due to changes in gastric microecology in the modern era. Gut 1998, 43,721–727
3. Ford, A.C.; Axon, A.T. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010, 15, 1–6.
4. Varbanova M, Malfertheiner P (2011) Bacterial load and degree of gastric mucosal inflammation in Helicobacter pylori infection.Dig Dis 29:592–599
5. Tyagi AK, Prasad S, Commentary: probiotic and technological properties of Lactobacillus spp. Strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol., 2015; 6: 433.
6. Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study, Caterina Holz et al 2014.
7. Non-Viable Lactobacillus reuteri DSMZ 17648 (PylopassTM) as a New Approachto Helicobacter pylori Control in Humans Heidrun Mehling 1 and Andreas Busjahn 2.
8. Mihai et al 2019: Lactobacillus Reuteri – An alternative in the first-line of Helicobacter pylori eradication.
9. Klausz G et al 2004: Effects of Helicobacter pylori infection on gastric inflammation and local cytokine production in histamine-deficient (histidine decarboxylase knock-out) mice.
10. Parolova et al 2019 – Gastric microbiota and probiotic opportunities in Helicobacter Pylori eradication in children.